Erlotinib, an epidermal growth factor receptor inhibitor slows the progression of murine diabetic nephropathy and this is associated with lower tubular and glomerular CHOP and lower glomerular GRP78/BiP and PERK expression. This evidence concerns the gene DDIT3 and diabetic kidney disease.